Post-earnings recap
Reported
Fri, Feb 9, 2018
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
25%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
The earnings report indicates that Arrowhead Pharmaceuticals is still facing challenges, particularly in managing costs. The stock's decline of 1.24% reflects investor concerns over the missed EPS target and lack of revenue data. Without updated guidance, investors may remain cautious about the company's short-term prospects.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.18 | N/A | -6.61% |
| Revenue | N/A | N/A | N/A |
Overall, management conveyed a cautious outlook, highlighting the need for strategic adjustments. They did not provide specific guidance for future quarters.
Management acknowledged the challenges faced in the quarter.
They emphasized ongoing efforts to improve operational efficiency.